A rapid B-type natriuretic peptide assay accurately diagnoses left ventricular dysfunction and heart failure: A multicenter evaluation

American Heart Journal

Volumn 144, Issue 5, 2002, Pages 834-839

  Wieczorek, Stacey J ^a,b,c,d,e   Wu, Alan H B ^a,b,c,d,e   Christenson, Robert ^a,b,c,d,e   Krishnaswamy, Padma ^a,b,c,d,e   Gottlieb, Stephen ^a,b,c,d,e   Rosano, Thomas ^a,b,c,d,e   Hager, David ^a,b,c,d,e   Gardetto, Nancy ^a,b,c,d,e   Chiu, Albert ^a,b,c,d,e   Bailly, Kathryn R ^a,b,c,d,e   Maisel, Alan ^a,b,c,d,e  

^a HARTFORD HOSPITAL   (United States)

^b UNIVERSITY OF MARYLAND   (United States)

^c ALBANY MEDICAL CENTER   (United States)

^d UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

^e VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRAIN NATRIURETIC PEPTIDE;

ADULT; AGED; ARTICLE; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DISEASE CLASSIFICATION; DISEASE SEVERITY; HEART FAILURE; HEART LEFT VENTRICLE FAILURE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MULTICENTER STUDY; PRIORITY JOURNAL; PROTEIN DETERMINATION;

EID: 0036849227     PISSN: 00028703     EISSN: None     Source Type: Journal    
DOI: 10.1067/mhj.2002.125623     Document Type: Article

References (29)

1. Mair J, Friedl W, Thomas S, et al. Natriuretic peptides in assessment of left ventricluar dysfunction. Scand J Clin Lab Invest 1999; 59(230 Suppl):132-42.
2. Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 1999;341:709-17.
3. Saito, Y, Nakao K, Itoh H. Brain natriuretic peptide is a novel cardiac hormone. Biochem Biophys Res Commun 1989;158:360-8.
4. Nakao K, Itoh H, Kambayama Y, et al. Rat brain natriuretic peptide: Isolation from rat heart and tissue distribution. Hypertension 1990;15:774-8.
5. Nakagawa O, Ogawa Y, Itoh H, et al. Rapid transciptional activation and early mRNA turnover of brain natriuretic peptide in cardiocyte hypertrophy. J Clin Invest 1995;96:1280-7.
6. Selvais P, Donckier J, Robert A, et al. Cardiac natriuretic peptides for diagnosis and risk stratification in heart failure: Influences of left ventricular dysfunction and coronary artery disease on cardiac hormonal activation. Eur J Clin Invest 1998;28:636-42.
7. Yoshimura M, Yasue H, Okumura K, et al. Different secretion patterns of atrial natriuretic peptide and brain natriuretic peptide in patients with congestive heart failure. Circulation 1993;87:464-9.
8. Yamamota K, Burnett J, Jougasaki M, et al. Superiority of brain natriuretic peptide as a hormonal marker of ventricular systolic and diastolic dysfunction and ventricular hypertrophy. Hypertension 1996;28:988-94.
9. Clerico A, Lervasi G, Del Chicca M, et al. Circulating levels of cardiac natriuretic peptides (ANP and BNP) measured by highly sensitive and specific immunoradiometric assays in normal subjects and in patients with different degrees of heart failure. J Endocrinol Invest 1998;21:170-9.
10. BNP Test Far Rapid Quantification of B-type Natriuretic Peptide [Package Insert]. San Diego, Calif: Biosite Diagnostics; 2000.
11. Wallen T, Landahl S, Hedner T, et al. Brain natriuretic peptide in an elderly population. J Intern Med 1997;242:307-11.
12. Waku S, Iida N, Ishihara T. Significance of brain natriuretic peptide measurement as a diagnostic indicator of cardiac function. Method Inform Med 2000;39:249-53.
13. Adams KF. Post hoc subgroup analysis and the truth of a clinical trial. Am Heart J 1998;136:751-8.
14. Drumholtz HM, Chen YT, Wan Y, et al. Predictors of readmission among elderly survivors of admission with heart failure. Am Heart J 2000;139:72-7.
15. Rich MW, Freedland KE. Effect of DRGs on three month readmission rate of geriatric patients with heart failure. Am J Public Health 1988;78:680-2.
16. Stevenson LW, Braunwald E. Recognition and management of patients with heart failure. In: Primary Cardiology. Philadelphia: WB Saunders Co; 1998. p. 310-29.
17. Vinson JM, Rich MW, Sperry JC, et al. Early readmission of elderly patients with heart failure. J Am Geriatr Soc 1990;38:1290-5.
18. Del Ry S, Giannessi D, Clerico A. Plasma brain natriuretic peptide measured by fully-automated immunoassay and by immunoradiometric compared. Clin Chem Lab Med 2001;39:446-50.
19. Vogeser M, Jacob K. B-type natriuretic peptide (BNP) - Validation of an immediate response assay. Clin Lab 2001;47:29-33.
20. Yasue H, Yoshimura M, Sumida H, et al. Localization and mechanism of secretion of B-type natriuretic peptide in comparison with those of A-type natriuretic peptide in normal subjects and patients with heart failure. Circulation 1994;90:195-203.
21. Nakao K, Mukoyama M, Hosoda K, et al. Biosynthesis, secretion and receptor selectivity of human brain natriuretic peptide. Can J Physiol Pharmacol 1991;87:1402-12.
22. Grantham JA, Burnett JC Jr. BNP: Increasing importance in the pathophysiology and diagnosis of congestive heart failure. Circulation 1997;96:388-90.
23. Haug C, Metzele A, Steffen J, et al. Increased brain natriuretic peptide and atrial peptide plasma concentration in dialysis-dependent chronic renal failure and in patients with elevated left ventricular filling pressure. Clin Invest 1994;72:430-4.
24. Dao Q, Krishnaswamy P, Kazanegra R, et al. Utility of B-natriuretic peptide (BNP) as a rapid point-of-care test for the emergency room diagnosis of congestive heart failure. J Am Coll Cardiol 2001;37:379-85.
25. Cheng V, Kazenagra R, Garcia A, et al. A rapid bedside test for B-natriuretic peptide (BNP) predicts outcomes in patients admitted for decompensated heart failure. J Am Coll Cardiol 2001;37:386-91.
26. Kazanagra R, Chen V, Garcia A, et al. A rapid test for B-natiuretic peptide (BNP) correlates with falling wedge pressures in patients treated for decompensated heart failure: A pilot study. J Card Fail 2001;7:21-9.
27. Yoshimura M, Yasue H, Tanaka H, et al. Responses of plasma concentrations of A type natriuretic peptide and B-type natriuretic peptide to alacepril, an angiotension-converting enzyme inhibitor, in patients with congestive heart failure. Br Heart J 1994;72:528-33.
28. Murdoch DR, McDonagh TA, Byrne J, et al. Titration of vasodilator therapy in chronic heart failure according to plasma brain natriuretic peptide concentration: Randomized comparison of the hemodynamic and neuroendocrine effects of tailored versus empirical therapy. Am Heart J 1999;138:1126-32.
29. Lee SC, Stevens TL, Sandberg SM, et al. The potential of brain natriuretic peptide as a biomarker for New York Heart Association class during outpatient treatment of heart failure. J Cardiac Fail 2002;8:149-54.